{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:35:24Z","timestamp":1794069324908,"version":"4.8.0"},"reference-count":171,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xphs.2026.104413","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:50:09Z","timestamp":1783918209000},"page":"104413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intraperitoneal route of administration: Present understanding and future usage"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6197-981X","authenticated-orcid":false,"given":"Jack","family":"Terry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0824-6577","authenticated-orcid":false,"given":"Michael","family":"Hageman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104413_bib0001","series-title":"Guyton and Hall Textbook of Medical Physiology E-Book: Guyton and Hall Textbook of Medical Physiology E-Book","author":"Hall","year":"2015"},{"key":"10.1016\/j.xphs.2026.104413_bib0002","series-title":"Medical Physiology","author":"Boron","year":"2017"},{"key":"10.1016\/j.xphs.2026.104413_bib0003","series-title":"Histology: A Text and Atlas with Cell and Molecular Biology","author":"Ross","year":"2002"},{"key":"10.1016\/j.xphs.2026.104413_bib0004","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3389\/fphys.2018.00738","article-title":"The Peritoneum: beyond the tissue - A review","volume":"9","author":"Isaza-Restrepo","year":"2018","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","article-title":"The histophysiology and pathophysiology of the peritoneum","volume":"49","author":"van Baal","year":"2017","journal-title":"Tissue Cell"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0006","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1440-1843.2002.00404.x","article-title":"Mesothelial cells: their structure, function and role in serosal repair","volume":"7","author":"Mutsaers","year":"2002","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0007","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3747\/pdi.2012.00323","article-title":"Alterations of intercellular junctions in peritoneal mesothelial cells from patients undergoing dialysis: effect of retinoic acid","volume":"35","author":"Retana","year":"2015","journal-title":"Perit Dial Int"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0008","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5935\/0101-2800.20140013","article-title":"Physiology of fluid and solute transport across the peritoneal membrane]","volume":"36","author":"Aguirre","year":"2014","journal-title":"J Bras Nefrol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0009","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1515\/pp-2016-0015","article-title":"Functional vascular anatomy of the peritoneum in health and disease","volume":"1","author":"Solass","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"10.1016\/j.xphs.2026.104413_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118456","article-title":"Therapeutic delivery to the peritoneal lymphatics: current understanding, potential treatment benefits and future prospects","volume":"567","author":"Sarfarazi","year":"2019","journal-title":"Int J Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2026.104413_bib0011","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/bjs.1800830804","article-title":"Peritoneal defences and peritoneum-associated lymphoid tissue","volume":"83","author":"Heel","year":"1996","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.xphs.2026.104413_bib0012","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/089686080102100512","article-title":"Expression of defensin antimicrobial peptides in the peritoneal cavity of patients on peritoneal dialysis","volume":"21","author":"Zarrinkalam","year":"2001","journal-title":"Perit Dial Int"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2026.104413_bib0013","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1177\/089686080902902S40","article-title":"Peritoneal defense mechanisms\u2013the effects of new peritoneal dialysis solutions","volume":"29","author":"Kazancioglu","year":"2009","journal-title":"Perit Dial Int"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0014","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/089686080602600207","article-title":"Peritoneal mesothelial cell culture and biology","volume":"26","author":"Yung","year":"2006","journal-title":"Perit Dial Int"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cellbi.2003.11.014","article-title":"Cultured peritoneal mesothelial cells exhibit apical primary cilia","volume":"28","author":"Bird","year":"2004","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.xphs.2026.104413_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/484167","article-title":"Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells","volume":"2012","author":"Yung","year":"2012","journal-title":"Mediat Inflamm"},{"issue":"6","key":"10.1016\/j.xphs.2026.104413_bib0017","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1053\/j.sempedsurg.2014.06.002","article-title":"Anatomy and physiology of the peritoneum","volume":"23","author":"Blackburn","year":"2014","journal-title":"Semin Pediatr Surg"},{"key":"10.1016\/j.xphs.2026.104413_bib0018","series-title":"Transport Kinetics, in Peritoneal Dialysis","first-page":"96","author":"Popovich","year":"1989"},{"key":"10.1016\/j.xphs.2026.104413_bib0019","series-title":"Peritoneal Dialysis","first-page":"178","article-title":"Continuous ambulatory peritoneal dialysis (CAPD) \u2014 worldwide experience","author":"Moncrief","year":"1981"},{"key":"10.1016\/j.xphs.2026.104413_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12575-009-9008-x","article-title":"Size and shape of protein molecules at the nanometer level determined by sedimentation, gel filtration, and electron microscopy","volume":"11","author":"Erickson","year":"2009","journal-title":"Biol Proced Online"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0021","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/ki.1991.216","article-title":"Computer simulations of peritoneal fluid transport in CAPD","volume":"40","author":"Rippe","year":"1991","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2026.104413_bib0022","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/089686089301302S09","article-title":"A three-pore model of peritoneal transport","volume":"13","author":"Rippe","year":"1993","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.xphs.2026.104413_bib0023","first-page":"3","article-title":"Clinical implications of a three-pore model of peritoneal transport","volume":"7","author":"Rippe","year":"1991","journal-title":"Adv Perit Dial"},{"issue":"5","key":"10.1016\/j.xphs.2026.104413_bib0024","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/ki.1989.115","article-title":"Simulations of peritoneal solute transport during CAPD. Application of two-pore formalism","volume":"35","author":"Rippe","year":"1989","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ki.1990.227","article-title":"A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD","volume":"38","author":"Stelin","year":"1990","journal-title":"Kidney Int"},{"issue":"Suppl 6","key":"10.1016\/j.xphs.2026.104413_bib0026","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ndt\/13.suppl_6.120","article-title":"Mathematical models for prescription and delivery in peritoneal dialysis","volume":"13","author":"Amici","year":"1998","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0027","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","article-title":"Intraperitoneal route of drug administration: should it Be used in experimental animal studies?","volume":"37","author":"Al Shoyaib","year":"2019","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0028","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00002216-198904000-00002","article-title":"Absorption of fluid and solutes from the peritoneal cavity. Theoretic and therapeutic implications and applications","volume":"35","author":"Mactier","year":"1989","journal-title":"ASAIO Trans"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0029","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7150\/thno.13907","article-title":"P-glycoprotein mediates postoperative peritoneal adhesion formation by enhancing phosphorylation of the chloride channel-3","volume":"6","author":"Deng","year":"2016","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.xphs.2026.104413_bib0030","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0011-3840(86)90007-9","article-title":"The greater omentum: its applicability to cancer surgery and cancer therapy","volume":"23","author":"Williams","year":"1986","journal-title":"Curr probl surg"},{"key":"10.1016\/j.xphs.2026.104413_bib0031","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000415204","article-title":"Principles and practice of intraperitoneal therapy","volume":"40","author":"Surbone","year":"1988","journal-title":"Antibiot Chemother(Basel)"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0032","doi-asserted-by":"crossref","first-page":"H15","DOI":"10.1152\/ajpheart.1985.248.1.H15","article-title":"Exchange of macromolecules between peritoneal cavity and plasma","volume":"248","author":"Flessner","year":"1985","journal-title":"Am J Physiol-Heart Circ Physiol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0033","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/089686089001000203","article-title":"Peritoneal defence mechanisms and Staphylococcus aureus in patients treated with continuous ambulatory peritoneal dialysis (CAPD)","volume":"10","author":"Davies","year":"1990","journal-title":"Perit Dial Int"},{"issue":"6","key":"10.1016\/j.xphs.2026.104413_bib0034","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1177\/089686080702700611","article-title":"The expression patterns of peritoneal defensins","volume":"27","author":"Grupp","year":"2007","journal-title":"Perit Dial Int"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/00365521.1970.12096584","article-title":"Transperitoneal exchange. IV. The effect of transperitoneal fluid transport on the transfer of solutes","volume":"5","author":"Aune","year":"1970","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104413_bib0036","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.immuni.2009.03.014","article-title":"Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens","volume":"30","author":"Rangel-Moreno","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.xphs.2026.104413_bib0037","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/archsurg.1963.01310150119027","article-title":"Peritoneal fluid ph after perforation of peptic ulcers: The myth of \"acid-peritonitis\"","volume":"87","author":"Howard","year":"1963","journal-title":"Arch Surg"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0038","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1148\/rg.233025712","article-title":"US of the Peritoneum","volume":"23","author":"Hanbidge","year":"2003","journal-title":"RadioGraphics"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0039","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/17425247.2020.1736551","article-title":"Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion","volume":"17","author":"Ceelen","year":"2020","journal-title":"Expert Opin Drug Deliv"},{"issue":"4_suppl","key":"10.1016\/j.xphs.2026.104413_bib0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/089686080002004S03","article-title":"Pathophysiology of peritoneal membrane failure","volume":"20","author":"Krediet","year":"2000","journal-title":"Perit Dial Int"},{"issue":"5041","key":"10.1016\/j.xphs.2026.104413_bib0041","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/2101123a0","article-title":"Peritoneal fluid volume and the oestrus cycle in mice","volume":"210","author":"Hartveit","year":"1966","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0042","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1523-1755.2005.00465.x","article-title":"Mini-peritoneal equilibration test: a simple and fast method to assess free water and small solute transport across the peritoneal membrane","volume":"68","author":"La Milia","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.xphs.2026.104413_bib0043","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/ckj\/sft122","article-title":"Peritoneal dialysis: from bench to bedside","volume":"6","author":"Krediet","year":"2013","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1016\/j.xphs.2026.104413_bib0044","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/sj.ki.5000183","article-title":"Peritoneal transport assessment by peritoneal equilibration test with 3.86% glucose: a long-term prospective evaluation","volume":"69","author":"La Milia","year":"2006","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0940-9602(97)80104-5","article-title":"The ultrastructure and computer imaging of the lymphatic stomata in the human pelvic peritoneum","volume":"179","author":"Li","year":"1997","journal-title":"Ann Anat"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0046","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejogrb.2008.01.014","article-title":"Peritoneal fluid flow influences anatomical distribution of endometriotic lesions: why Sampson seems to be right","volume":"138","author":"Bricou","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0047","first-page":"373","article-title":"Common peritoneal disorders: what the physician should know","volume":"18","author":"Weledji","year":"2023","journal-title":"Prz Gastroenterol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0048","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1148\/95.3.547","article-title":"The spread and localization of acute intraperitoneal effusions","volume":"95","author":"Meyers","year":"1970","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0049","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ar.1091770307","article-title":"The ultrastructural morphology and possible functional significance of mesothelial microvilli","volume":"177","author":"Andrews","year":"1973","journal-title":"Anat Rec"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/aja.1001490111","article-title":"Absorption from the peritoneal cavity: SEM study of the mesothelium covering the peritoneal surface of the muscular portion of the diaphragm","volume":"149","author":"Tsilibary","year":"1977","journal-title":"Am J Anat"},{"issue":"5","key":"10.1016\/j.xphs.2026.104413_bib0051","first-page":"623","article-title":"The regional difference of pleural mesothelial cells in rabbits","volume":"110","author":"Wang","year":"1974","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0052","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1083\/jcb.82.3.783","article-title":"Regulation of surface topography of mouse peritoneal cells. Formation of microvilli and vesiculated pits on omental mesothelial cells by serum and other proteins","volume":"82","author":"Madison","year":"1979","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0053","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/(SICI)1096-9896(199611)180:3<333::AID-PATH659>3.0.CO;2-Y","article-title":"Changes in the concentration of microvilli on the free surface of healing mesothelium are associated with alterations in surface membrane charge","volume":"180","author":"Mutsaers","year":"1996","journal-title":"J Pathol"},{"issue":"7","key":"10.1016\/j.xphs.2026.104413_bib0054","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1124\/dmd.118.080697","article-title":"Use of subcutaneous and intraperitoneal administration methods to facilitate cassette dosing in microdialysis studies in rats","volume":"46","author":"Durk","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.xphs.2026.104413_bib0055","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1124\/dmd.115.064204","article-title":"Use of cassette dosing to enhance the throughput of rat brain microdialysis studies","volume":"43","author":"Deshmukh","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0056","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/03639045.2013.771645","article-title":"Subcutaneous administration of nano- and microsuspensions of poorly soluble compounds to rats","volume":"40","author":"Sigfridsson","year":"2014","journal-title":"Drug Dev Ind Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2026.104413_bib0057","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.3109\/03639045.2012.738684","article-title":"Evaluation of exposure properties after injection of nanosuspensions and microsuspenions into the intraperitoneal space in rats","volume":"39","author":"Sigfridsson","year":"2013","journal-title":"Drug Dev Ind Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0058","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/03639045.2010.505927","article-title":"Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development","volume":"37","author":"Sigfridsson","year":"2011","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0059","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1211\/0022357055380","article-title":"Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice","volume":"57","author":"Shimada","year":"2005","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2026.104413_bib0060","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.2147\/IJN.S32880","article-title":"Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation","volume":"7","author":"Hu","year":"2012","journal-title":"Int J Nanomed"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0061","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1211\/0022357001773670","article-title":"Oral, intraperitoneal and intravenous pharmacokinetics of Deramciclane and its N-desmethyl metabolite in the rat","volume":"52","author":"Nemes","year":"2000","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0062","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13139-011-0087-7","article-title":"Comparison of the intraperitoneal, retroorbital and per oral routes for F-18 FDG administration as effective alternatives to intravenous administration in mouse tumor models using small animal PET\/CT studies","volume":"45","author":"Kim","year":"2011","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0063","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70178","article-title":"Development and application of an LC\u2013MS method for the pharmacokinetics and pharmacodynamics of oral therapeutic efficacy of Nalfurafine","volume":"138","author":"Sondhauss","year":"2026","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0064","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/pharmaceutics16010053","article-title":"Systemic and brain pharmacokinetics of Milnacipran in mice: comparison of intraperitoneal and intravenous administration","volume":"16","author":"Bagchi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2026.104413_bib0065","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902017000116081","article-title":"In vitro intestinal permeability studies, pharmacokinetics and tissue distribution of 6-methylcoumarin after oral and intraperitoneal administration in Wistar rats","volume":"53","author":"C\u00e1rdenas","year":"2017","journal-title":"Braz J Pharm Sci"},{"issue":"39","key":"10.1016\/j.xphs.2026.104413_bib0066","doi-asserted-by":"crossref","first-page":"41032","DOI":"10.1021\/acsomega.4c06604","article-title":"Comparative pharmacokinetics and tissue distribution of hexahydrocurcumin following intraperitoneal vs oral administration in mice using LC-MS\/MS","volume":"9","author":"Chaiyasaeng","year":"2024","journal-title":"ACS Omega"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0067","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0068","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-3565(24)38868-8","article-title":"Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study1","volume":"295","author":"Gerasimov","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0069","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/toxsci\/kfab049","article-title":"Toxicokinetic and genotoxicity study of NNK in male Sprague Dawley rats following nose-only inhalation exposure, intraperitoneal injection, and oral gavage","volume":"182","author":"Hu","year":"2021","journal-title":"Toxicol Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0070","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1208\/s12248-012-9401-2","article-title":"Pharmacokinetics and tissue disposition of lenalidomide in mice","volume":"14","author":"Rozewski","year":"2012","journal-title":"AAPS J"},{"issue":"23","key":"10.1016\/j.xphs.2026.104413_bib0071","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1182\/blood.V126.23.4579.4579","article-title":"Pharmacokinetics and tissue distribution of hydroxyurea in a mouse model","volume":"126","author":"Marahatta","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0072","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/faat.1995.1150","article-title":"Metabolism and testicular toxicity of 1,3-dinitrobenzene in the rat: effect of route of administration","volume":"28","author":"McEuen","year":"1995","journal-title":"Fundam Appl Toxicol"},{"key":"10.1016\/j.xphs.2026.104413_bib0073","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jpsychires.2019.02.003","article-title":"Brain penetration of ketamine: intranasal delivery VS parenteral routes of administraion","volume":"112","author":"Naidoo","year":"2019","journal-title":"J Psychiatr Res"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0074","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269881118812095","article-title":"Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine","volume":"33","author":"Highland","year":"2019","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.xphs.2026.104413_bib0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jpba.2017.02.051","article-title":"Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry","volume":"139","author":"Wang","year":"2017","journal-title":"J Pharm Biomed Anal"},{"issue":"14","key":"10.1016\/j.xphs.2026.104413_bib0076","doi-asserted-by":"crossref","first-page":"14465","DOI":"10.1021\/acs.jmedchem.5c00507","article-title":"Antitumor efficacy of 1,2,4-triazole-based VCP\/p97 allosteric inhibitors","volume":"68","author":"Green","year":"2025","journal-title":"J Med Chem"},{"issue":"14","key":"10.1016\/j.xphs.2026.104413_bib0077","doi-asserted-by":"crossref","first-page":"12261","DOI":"10.1021\/acs.jmedchem.4c00962","article-title":"More than an Amide bioisostere: discovery of 1,2,4-triazole-containing pyrazolo[1,5-a]pyrimidine host CSNK2 inhibitors for combatting \u03b2-coronavirus replication","volume":"67","author":"Ong","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.xphs.2026.104413_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115447","article-title":"Pharmacological effects of mTORC1\/C2 inhibitor in a preclinical model of NASH progression","volume":"167","author":"Arora","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"42","key":"10.1016\/j.xphs.2026.104413_bib0079","doi-asserted-by":"crossref","first-page":"39546","DOI":"10.1021\/acsomega.3c05377","article-title":"Optimization of 3-cyano-7-cyclopropylamino-pyrazolo[1,5-a]pyrimidines toward the development of an In vivo chemical probe for CSNK2A","volume":"8","author":"Yang","year":"2023","journal-title":"ACS Omega"},{"issue":"16","key":"10.1016\/j.xphs.2026.104413_bib0080","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1021\/acs.jmedchem.3c00837","article-title":"Design, synthesis, and biological evaluation of novel P2\u00d77 receptor antagonists for the treatment of septic acute kidney injury","volume":"66","author":"Zhang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.xphs.2026.104413_bib0081","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3390\/molecules27031017","article-title":"Pharmacokinetic characterization of the DDAH1 inhibitors ZST316 and ZST152 in mice using a HPLC-MS\/MS method","volume":"27","author":"Mangoni","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.xphs.2026.104413_bib0082","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1007\/s43440-021-00312-5","article-title":"Pharmacokinetics and tissue distribution of hydrazinocurcumin in rats","volume":"73","author":"Satyavert","year":"2021","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.xphs.2026.104413_bib0083","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s13318-018-0474-x","article-title":"Pharmacokinetics of the P-gp inhibitor Tariquidar in rats after intravenous, oral, and intraperitoneal administration","volume":"43","author":"Matzneller","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"8","key":"10.1016\/j.xphs.2026.104413_bib0084","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1124\/dmd.112.045930","article-title":"Brain distribution and bioavailability of elacridar after different routes of administration in the mouse","volume":"40","author":"Sane","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/ph17020179","article-title":"Early stage preclinical formulation strategies to alter the pharmacokinetic profile of two small molecule therapeutics","volume":"17","author":"An","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.xphs.2026.104413_bib0086","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/jvp.13091","article-title":"Pharmacokinetics of cefquinome in rainbow trout (Oncorhynchus mykiss) after intravascular, intraperitoneal, and oral administrations","volume":"45","author":"Durna Corum","year":"2022","journal-title":"J Vet Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.xphs.2026.104413_bib0087","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1080\/19440049.2022.2121429","article-title":"Plasma and muscle tissue disposition of enrofloxacin in Nile tilapia (Oreochromis niloticus) after intravascular, intraperitoneal, and oral administrations","volume":"39","author":"Corum","year":"2022","journal-title":"Food Addit Contam: A"},{"issue":"12","key":"10.1016\/j.xphs.2026.104413_bib0088","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1080\/09168451.2015.1062711","article-title":"Absorption and plasma kinetics of collagen tripeptide after peroral or intraperitoneal administration in rats","volume":"79","author":"Yamamoto","year":"2015","journal-title":"Biosci Biotechnol Biochem"},{"key":"10.1016\/j.xphs.2026.104413_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171075","article-title":"Gel-forming therapeutic peptide exhibits sustained delivery and efficacy in a mouse model of triple-negative breast cancer","volume":"169","author":"Patil","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.xphs.2026.104413_bib0090","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.3390\/pharmaceutics15122745","article-title":"Bioanalysis of the ex vivo labile PACE4 inhibitory peptide Ac-[d-Leu]LLLRVK-amba in whole blood using ultra-performance liquid chromatography-tandem mass spectrometry quantification","volume":"15","author":"Sauter","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0091","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ddr.1195","article-title":"Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1","volume":"53","author":"Parkes","year":"2001","journal-title":"Drug Dev Res"},{"issue":"6","key":"10.1016\/j.xphs.2026.104413_bib0092","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bcpt.13731","article-title":"Pharmacokinetics of glucagon after intravenous, intraperitoneal and subcutaneous administration in a pig model","volume":"130","author":"Teigen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"10","key":"10.1016\/j.xphs.2026.104413_bib0093","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1089\/jir.2013.0067","article-title":"PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a Human tumor xenograft in athymic mice","volume":"34","author":"Fam","year":"2014","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"10.1016\/j.xphs.2026.104413_bib0094","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1203\/pdr.0b013e31805341dc","article-title":"Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats","volume":"61","author":"Statler","year":"2007","journal-title":"Pediatr Res"},{"issue":"7","key":"10.1016\/j.xphs.2026.104413_bib0095","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/19420862.2019.1626652","article-title":"Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4","volume":"11","author":"Griffiths","year":"2019","journal-title":"mAbs"},{"issue":"Pt B","key":"10.1016\/j.xphs.2026.104413_bib0096","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-364935-5.50013-4","article-title":"Pharmacokinetic parameters and biodistribution of soluble cytokine receptors","volume":"34","author":"Jacobs","year":"1993","journal-title":"Int Rev Exp Pathol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104413_bib0097","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2008-07-168146","article-title":"Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody","volume":"113","author":"Goldenberg","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0098","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1021\/mp400004a","article-title":"Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice","volume":"10","author":"Sumbria","year":"2013","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0099","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2516.2011.02735.x","article-title":"Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice","volume":"18","author":"Shi","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.xphs.2026.104413_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122126","article-title":"HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis","volume":"625","author":"Wang","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104413_bib0101","article-title":"Excipient selection","author":"Pramanick","year":"2013","journal-title":"Parenter Formul Dev"},{"key":"10.1016\/j.xphs.2026.104413_bib0102","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3390\/nu10111660","article-title":"Tissular distribution and metabolism of trans-\u03b5-viniferin after intraperitoneal injection in rat","volume":"10","author":"Courtois","year":"2018","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0103","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/can.2021.0181","article-title":"Simultaneous assessment of serum levels and pharmacologic effects of cannabinoids on endocannabinoids and N-acylethanolamines by liquid chromatography\u2013Tandem mass spectrometry","volume":"8","author":"Couttas","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.xphs.2026.104413_bib0104","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3390\/ijms23042232","article-title":"Cannabidiol downregulates myocardial de novo ceramide synthesis pathway in a rat model of high-fat diet-induced obesity","volume":"23","author":"Charytoniuk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xphs.2026.104413_bib0105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/nu16030424","article-title":"A combination of a dopamine receptor 2 agonist and a Kappa opioid receptor antagonist synergistically reduces weight in diet-induced obese rodents","volume":"16","author":"Cicu\u00e9ndez","year":"2024","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.xphs.2026.104413_bib0106","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00213-021-05806-x","article-title":"Noradrenergic contributions to cue-driven risk-taking and impulsivity","volume":"238","author":"Chernoff","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.xphs.2026.104413_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106540","article-title":"Comparison of the beneficial effects of RS504393, maraviroc and cenicriviroc on neuropathic pain-related symptoms in rodents: behavioral and biochemical analyses","volume":"84","author":"Kwiatkowski","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.xphs.2026.104413_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2021.113668","article-title":"Peripherally administered amylin inhibits stress-like behaviors and enhances cognitive performance","volume":"244","author":"Laugero","year":"2022","journal-title":"Physiol Behav"},{"key":"10.1016\/j.xphs.2026.104413_bib0109","article-title":"Administration of chiglitazar reverses chronic stress-induced depressive-like symptoms in mice via activation of hippocampal ppar\u03b1 and BDNF","volume":"Volume 16 - 2025","author":"Zhou","year":"2025","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.vascn.2006.02.006","article-title":"Effect of commonly used vehicles on gastrointestinal, renal, and liver function in rats","volume":"54","author":"Pestel","year":"2006","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"5","key":"10.1016\/j.xphs.2026.104413_bib0111","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1211\/0022357023303","article-title":"Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles","volume":"56","author":"Yokogawa","year":"2004","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104413_bib0112","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ki.1990.282","article-title":"Tracer kinetics and actions of oral and intraperitoneal 1,25-dihydroxyvitamin D3 administration in rats","volume":"38","author":"Vieth","year":"1990","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.xphs.2026.104413_bib0113","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/jps.2600810707","article-title":"Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat","volume":"81","author":"Pec","year":"1992","journal-title":"J pharm sci"},{"key":"10.1016\/j.xphs.2026.104413_bib0114","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1377081","article-title":"Novel multitarget analgesic candidate SZV-1287 demonstrates potential disease-modifying effects in the monoiodoacetate-induced osteoarthritis mouse model","volume":"15","author":"Horv\u00e1th","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xphs.2026.104413_bib0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neuro.2021.08.002","article-title":"Effects of route of administration on neural exposure to platinum-based chemotherapy treatment: a pharmacokinetic study in rat","volume":"86","author":"Housley","year":"2021","journal-title":"NeuroToxicology"},{"issue":"6","key":"10.1016\/j.xphs.2026.104413_bib0116","first-page":"779","article-title":"Effects of repeated intraperitoneal injection of pharmaceutical-grade and nonpharmaceutical-grade corn oil in female C57BL\/6J mice","volume":"56","author":"Hubbard","year":"2017","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"10.1016\/j.xphs.2026.104413_bib0117","first-page":"685","article-title":"Myrcene salvages rotenone-induced loss of dopaminergic neurons by inhibiting oxidative stress","volume":"28","author":"Azimullah","year":"2023","journal-title":"Inflamm Apoptosis Autophagy, Mol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0118","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12640-015-9579-z","article-title":"Glycyrrhizic acid attenuates neuroinflammation and oxidative stress in Rotenone model of Parkinson's Disease","volume":"29","author":"Ojha","year":"2016","journal-title":"Neurotox Res"},{"issue":"null","key":"10.1016\/j.xphs.2026.104413_bib0119","first-page":"5499","article-title":"Neuroprotective potential of ferulic acid in the rotenone model of Parkinson\u2019s disease. Drug design","volume":"9","author":"Ojha","year":"2015","journal-title":"Dev Ther"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12868-016-0293-4","article-title":"Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone","volume":"17","author":"Javed","year":"2016","journal-title":"BMC Neurosci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0121","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/0975-7406.124303","article-title":"A cyclodextrin formulation to improve use of the anesthetic tribromoethanol (Avertin\u00ae)","volume":"6","author":"McDowell","year":"2014","journal-title":"J Pharm Bioallied Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0122","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2008.01.043","article-title":"In vivo antiviral activity of ribavirin\/alpha-cyclodextrin complex: evaluation on experimental measles virus encephalitis in mice","volume":"357","author":"Jeulin","year":"2008","journal-title":"Int J Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2026.104413_bib0123","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.patbio.2006.07.008","article-title":"Evaluation by Q-RTPCR of the efficacy of ribavirin complexed with beta-cyclodextrin against measles virus in a mouse encephalitis model","volume":"54","author":"Jeulin","year":"2006","journal-title":"Pathol Biol"},{"key":"10.1016\/j.xphs.2026.104413_bib0124","series-title":"Biomarkers in Toxicology","first-page":"7","article-title":"Chapter 2 - rodent models for toxicity testing and biomarkers","author":"Gad","year":"2019"},{"key":"10.1016\/j.xphs.2026.104413_bib0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.addr.2016.07.001","article-title":"Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis\u2014Mission possible?","volume":"108","author":"Dakwar","year":"2017","journal-title":"Adv drug deliv rev"},{"key":"10.1016\/j.xphs.2026.104413_bib0126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01932691.2025.2526053","article-title":"Design of experiments-based optimization of rutin-loaded nanostructured lipid carriers: characterization, pharmacokinetics, and stability evaluation","author":"Chalikwar","year":"2025","journal-title":"J Dispers Sci Technol"},{"issue":"6","key":"10.1016\/j.xphs.2026.104413_bib0127","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/jps.2600630630","article-title":"Comparison among four vehicles and four routes for administering \u22069-tetrahydrocannabinol","volume":"63","author":"Duane Sofia","year":"1974","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0128","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.2042-7158.2011.01388.x","article-title":"Pharmacokinetics and tissue distribution profile of icariin propylene glycol-liposome intraperitoneal injection in mice","volume":"64","author":"Yang","year":"2012","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2026.104413_bib0129","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3390\/pharmaceutics15051480","article-title":"Targeted fisetin-encapsulated \u03b2-cyclodextrin nanosponges for breast cancer","volume":"15","author":"Aboushanab","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2026.104413_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122787","article-title":"Pharmacokinetic evaluation of poorly soluble compounds formulated as nano- or microcrystals after intraperitoneal injection to mice","volume":"636","author":"Aluri","year":"2023","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0131","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00210-024-03339-6","article-title":"Azilsartan as a preventive agent against cyclophosphamide-induced testicular injury in male rats","volume":"398","year":"2025","journal-title":"Naunyn - Schmiedeb Arch Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0132","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4149\/gpb_2016004","article-title":"The tolerability of dextran-coated iron oxide nanoparticles during in vivo observation of the rats","volume":"35","author":"Popa","year":"2016","journal-title":"Gen Physiol Biophys"},{"key":"10.1016\/j.xphs.2026.104413_bib0133","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.msec.2018.07.012","article-title":"Carbon nanoparticles suspension injection for the delivery of doxorubicin: comparable efficacy and reduced toxicity","volume":"92","author":"Huang","year":"2018","journal-title":"Mater Sci Eng: C"},{"key":"10.1016\/j.xphs.2026.104413_bib0134","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121189","article-title":"The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis","volume":"279","author":"Kim","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0136","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2026.104413_bib0137","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114422","article-title":"Intraperitoneal administration of doxorubicin-encapsulated Brucea javanica oil nanoemulsion against malignant ascites","volume":"202","author":"Dai","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0138","doi-asserted-by":"crossref","first-page":"918","DOI":"10.21037\/tcr.2019.12.62","article-title":"Brucea javanica oil emulsion suppresses tumor growth in human cervical cancer cells through inhibition of the E6 oncogene and induction of apoptosis","volume":"9","author":"Ye","year":"2020","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.xphs.2026.104413_bib0139","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/jfb10040055","article-title":"Double-emulsion copolyester microcapsules for sustained intraperitoneal release of carboplatin","volume":"10","author":"Cymbaluk-P\u0142oska","year":"2019","journal-title":"J Funct Biomater"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0168-3659(00)00370-9","article-title":"Sustained elevated plasma aprotinin concentration in mice following intraperitoneal injections of w\/o emulsions incorporating aprotinin","volume":"71","author":"Bjerregaard","year":"2001","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2026.104413_bib0141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121904","article-title":"Effects of particle size and release property of paclitaxel-loaded nanoparticles on their peritoneal retention and therapeutic efficacy against mouse malignant ascites","volume":"623","author":"Kono","year":"2022","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0142","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ijpharm.2012.02.025","article-title":"Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice","volume":"427","author":"Ragelle","year":"2012","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0143","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jps.23450","article-title":"Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability","volume":"102","author":"Sane","year":"2013","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2026.104413_bib0144","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1208\/s12249-018-1120-2","article-title":"Evaluating the accelerated blood clearance phenomenon of PEGylated nanoemulsions in rats by intraperitoneal administration","volume":"19","author":"Su","year":"2018","journal-title":"AAPS PharmSciTech"},{"issue":"12","key":"10.1016\/j.xphs.2026.104413_bib0145","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00723-020-01242-w","article-title":"New aspects of biodistribution of perfluorocarbon emulsions in rats: Thymus imaging","volume":"51","author":"Pavlova","year":"2020","journal-title":"Appl Magn Reson"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0146","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/156720105774370267","article-title":"Engineering of nanoemulsions for drug delivery","volume":"2","author":"Dipak","year":"2005","journal-title":"Curr Drug Deliv"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0147","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.108.140095","article-title":"Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer","volume":"327","author":"Lu","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0148","first-page":"627","article-title":"Targeting the peritoneum with novel drug delivery systems in peritoneal carcinomatosis: a review of the literature","volume":"35","author":"Van Oudheusden","year":"2015","journal-title":"Anticancer Res"},{"issue":"Suppl 4","key":"10.1016\/j.xphs.2026.104413_bib0149","first-page":"iv23","article-title":"Peritoneal dialysis catheter placement technique and complications","volume":"1","author":"Peppelenbosch","year":"2008","journal-title":"NDT Plus"},{"issue":"7","key":"10.1016\/j.xphs.2026.104413_bib0150","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3109\/1061186X.2014.931406","article-title":"Thermosensitive poly-(d,l-lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly-(d,l-lactide-co-glycolide) hydrogels for multi-drug delivery","volume":"22","author":"Cho","year":"2014","journal-title":"J Drug Target"},{"issue":"20","key":"10.1016\/j.xphs.2026.104413_bib0151","doi-asserted-by":"crossref","first-page":"6443","DOI":"10.3390\/jcm12206443","article-title":"The role of prophylactic and adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention of peritoneal metastases in advanced colorectal cancer","volume":"12","author":"Sun","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0152","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/cancers12010034","article-title":"Overcoming drug resistance by taking advantage of physical principles: pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"12","author":"Nadiradze","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xphs.2026.104413_bib0153","series-title":"Exploring Drug Delivery to the Peritoneum","first-page":"195","article-title":"Drug delivery systems to the peritoneum: current status and future perspectives","author":"Joshi","year":"2023"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0154","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jog.15469","article-title":"Intraperitoneal instillation versus wound infiltration for postoperative pain relief after cesarean delivery: a prospective, randomized, double-blind, placebo-controlled trial","volume":"49","author":"Dagasan Cetin","year":"2023","journal-title":"J Obs Gynaecol Res"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0155","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1213\/ANE.0000000000002136","article-title":"Intraperitoneal instillation of local anesthetics: is this a suitable alternative for postcesarean pain relief without toxicity profiling?","volume":"125","author":"Jha","year":"2017","journal-title":"Anesth Analg"},{"key":"10.1016\/j.xphs.2026.104413_bib0156","unstructured":"Therapeutic monoclonal antibodies approved or in regularoty review. Antib Soc."},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0157","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2205540","article-title":"A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations","volume":"15","author":"Ghosh","year":"2023","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0158","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1586\/17434440.2014.882227","article-title":"Prefilled devices for parenteral applications","volume":"11","author":"Gurman","year":"2014","journal-title":"Expert Rev Med Devices"},{"issue":"8","key":"10.1016\/j.xphs.2026.104413_bib0159","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103877","article-title":"Current and emerging strategies for subcutaneous delivery of high-concentration and high-dose antibody therapeutics","volume":"114","author":"Ren","year":"2025","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104413_bib0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1208\/s12248-025-01132-8","article-title":"Insights from a survey of drug formulation experts: challenges and preferences in high-concentration subcutaneous biologic drug development","volume":"27","author":"Desai","year":"2025","journal-title":"Aaps j"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0161","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2285277","article-title":"Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume","volume":"15","author":"Desai","year":"2023","journal-title":"MAbs"},{"issue":"6","key":"10.1016\/j.xphs.2026.104413_bib0162","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2337\/diacare.9.6.575","article-title":"Free-insulin profiles after intraperitoneal, intramuscular, and subcutaneous insulin administration","volume":"9","author":"Micossi","year":"1986","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0163","first-page":"19","article-title":"The intraperitoneal injection of saline solution","volume":"XV","author":"Blackfan","year":"1918","journal-title":"Am J Dis Child"},{"issue":"19","key":"10.1016\/j.xphs.2026.104413_bib0164","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMra2100152","article-title":"Peritoneal dialysis","volume":"385","author":"Teitelbaum","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.xphs.2026.104413_bib0165","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0022-3565(25)28988-1","article-title":"The route of absorption of intraperitoneally administered compounds","volume":"178","author":"Lukas","year":"1971","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0166","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/039139880502800204","article-title":"A short review of experimental peritoneal sclerosis: from mice to men","volume":"28","author":"Gotloib","year":"2005","journal-title":"Int J Artif Organs"},{"issue":"13","key":"10.1016\/j.xphs.2026.104413_bib0167","first-page":"3434","article-title":"Effect of intraperitoneal injection volume and antibody protein dose on the pharmacokinetics of intraperitoneally administered IgG2a kappa murine monoclonal antibody in the rat","volume":"51","author":"Barrett","year":"1991","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.xphs.2026.104413_bib0168","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1023\/A:1018970617104","article-title":"Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration","volume":"11","author":"Bredberg","year":"1994","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0169","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","article-title":"High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis","volume":"244","author":"Esquis","year":"2006","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.xphs.2026.104413_bib0170","first-page":"Br1","article-title":"A study of the effect of temperature on the pharmacokinetic profile of raltitrexed administered by intraperitoneal route in the rat","volume":"11","author":"Bendavid","year":"2005","journal-title":"Med Sci Monit"},{"issue":"2","key":"10.1016\/j.xphs.2026.104413_bib0171","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s002800050721","article-title":"Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model","volume":"41","author":"Jacquet","year":"1998","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926002625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926002625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:25:45Z","timestamp":1790803545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926002625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":171,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0022354926002625"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104413","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal route of administration: Present understanding and future usage","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"104413"}}